New atypical antipsychotics for schizophrenia

Iloperidone

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal symptoms than D2 receptor antagonist antipsychotics. In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral doses from 12 to 24 mg. It was more effective than placebo in reducing positive and nega-tive syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as haloperidol and risperidone in post-hoc analysis. Its long-term efficacy was equivalent to that of haloperidol. The most common adverse events were dizziness, dry mouth, dyspepsia and somnolence, with few extrapyramidal symptoms and metabolic changes in short- and long-term studies in adults. Akathisia was rare, but prolongation of the corrected QT (QTc) interval was comparable to haloperidol and ziprasidone, which is of particular concern. Further comparative studies are needed to clarify the benefit/risk profile of iloperidone and its role in the treatment of schizophrenia.

Original languageEnglish
Pages (from-to)33-48
Number of pages16
JournalDrug Design, Development and Therapy
Issue number4
Publication statusPublished - 2010

Fingerprint

Haloperidol
Antipsychotic Agents
Schizophrenia
Risperidone
Brief Psychiatric Rating Scale
Serotonin 5-HT2 Receptor Antagonists
Psychomotor Agitation
Dyspepsia
Dizziness
Mouth
Dopamine
Serotonin
Therapeutics
Placebos
Pharmaceutical Preparations
iloperidone

Keywords

  • Efficacy
  • Iloperidone
  • Pharmacokinetics
  • Pharmacology
  • Safety

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

New atypical antipsychotics for schizophrenia : Iloperidone. / Caccia, Silvio; Pasina, Luca; Nobili, Alessandro.

In: Drug Design, Development and Therapy, No. 4, 2010, p. 33-48.

Research output: Contribution to journalArticle

@article{c80289a9e8ac4c2a9a7d3700b8cf0c0f,
title = "New atypical antipsychotics for schizophrenia: Iloperidone",
abstract = "The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal symptoms than D2 receptor antagonist antipsychotics. In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral doses from 12 to 24 mg. It was more effective than placebo in reducing positive and nega-tive syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as haloperidol and risperidone in post-hoc analysis. Its long-term efficacy was equivalent to that of haloperidol. The most common adverse events were dizziness, dry mouth, dyspepsia and somnolence, with few extrapyramidal symptoms and metabolic changes in short- and long-term studies in adults. Akathisia was rare, but prolongation of the corrected QT (QTc) interval was comparable to haloperidol and ziprasidone, which is of particular concern. Further comparative studies are needed to clarify the benefit/risk profile of iloperidone and its role in the treatment of schizophrenia.",
keywords = "Efficacy, Iloperidone, Pharmacokinetics, Pharmacology, Safety",
author = "Silvio Caccia and Luca Pasina and Alessandro Nobili",
year = "2010",
language = "English",
pages = "33--48",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - New atypical antipsychotics for schizophrenia

T2 - Iloperidone

AU - Caccia, Silvio

AU - Pasina, Luca

AU - Nobili, Alessandro

PY - 2010

Y1 - 2010

N2 - The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal symptoms than D2 receptor antagonist antipsychotics. In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral doses from 12 to 24 mg. It was more effective than placebo in reducing positive and nega-tive syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as haloperidol and risperidone in post-hoc analysis. Its long-term efficacy was equivalent to that of haloperidol. The most common adverse events were dizziness, dry mouth, dyspepsia and somnolence, with few extrapyramidal symptoms and metabolic changes in short- and long-term studies in adults. Akathisia was rare, but prolongation of the corrected QT (QTc) interval was comparable to haloperidol and ziprasidone, which is of particular concern. Further comparative studies are needed to clarify the benefit/risk profile of iloperidone and its role in the treatment of schizophrenia.

AB - The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Iloperidone is a new dopamine type 2/serotonin type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal symptoms than D2 receptor antagonist antipsychotics. In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral doses from 12 to 24 mg. It was more effective than placebo in reducing positive and nega-tive syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as haloperidol and risperidone in post-hoc analysis. Its long-term efficacy was equivalent to that of haloperidol. The most common adverse events were dizziness, dry mouth, dyspepsia and somnolence, with few extrapyramidal symptoms and metabolic changes in short- and long-term studies in adults. Akathisia was rare, but prolongation of the corrected QT (QTc) interval was comparable to haloperidol and ziprasidone, which is of particular concern. Further comparative studies are needed to clarify the benefit/risk profile of iloperidone and its role in the treatment of schizophrenia.

KW - Efficacy

KW - Iloperidone

KW - Pharmacokinetics

KW - Pharmacology

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=77953668586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953668586&partnerID=8YFLogxK

M3 - Article

SP - 33

EP - 48

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

IS - 4

ER -